Human Genome Epidemiology Literature Finder
Records 1 - 18 (of 18 Records) |
Query Trace: Ovarian Neoplasms and MDM2[original query] |
---|
No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer letters 2006 Aug 240 (2): 195-7. Campbell Ian G, Eccles Diana M, Choong David Y |
Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes, chromosomes & cancer 2007 Mar 46 (3): 239-47. Galic Vijaya, Willner Julia, Wollan Melissa, Garg Ruchi, Garcia Rochelle, Goff Barbara A, Gray Heidi J, Swisher Elizabeth |
MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast cancer research and treatment 2008 Oct 111 (3): 497-504. Yarden Ronit I, Friedman Eitan, Metsuyanim Sally, Olender Tsviya, Ben-Asher Edna, Papa Moshe Z |
MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology 2008 Jun 74 (1-2): 84-87. Krekac D, Brozkova K, Knoflickova D, Hrstka R, Muller P, Nenutil R, Vojtesek B |
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. The Journal of pathology 2010 May 221 (1): 49-56. Ahmed Ahmed Ashour, Etemadmoghadam Dariush, Temple Jillian, Lynch Andy G, Riad Mohamed, Sharma Raghwa, Stewart Colin, Fereday Sian, Caldas Carlos, Defazio Anna, Bowtell David, Brenton James |
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer cell 2011 Feb 19 (2): 273-82. Knappskog Stian, Bjørnslett Merete, Myklebust Line M, Huijts Petra E A, Vreeswijk Maaike P, Edvardsen Hege, Guo Yongli, Zhang Xuemei, Yang Ming, Ylisaukko-Oja Sanna K, Alhopuro Pia, Arola Johanna, Tollenaar Rob A E M, van Asperen Christi J, Seynaeve Caroline, Staalesen Vidar, Chrisanthar Ranjan, Løkkevik Erik, Salvesen Helga B, Evans D Gareth, Newman William G, Lin Dongxin, Aaltonen Lauri A, Børresen-Dale Anne-Lise, Tell Grethe S, Stoltenberg Camilla, Romundstad Pål, Hveem Kristian, Lillehaug Johan R, Vatten Lars, Devilee Peter, Dørum Anne, Lønning Per |
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. European journal of cancer (Oxford, England : 1990) 2011 Nov . Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC, Romundstad P, Hveem K, Vatten L, Salvesen HB, Lønning PE |
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers. BMC cancer 2012 Oct 12 (1): 1. Bjørnslett M, Knappskog S, Lønning PE, Dørum A |
The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls. PloS one 2013 8 (1): 1. Ma YY, Guan TP, Yao HB, Yu S, Chen LG, Xia YJ, He XJ, Wang HJ, Jiang XT, Tao HQ |
Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. International journal of cancer. Journal international du cancer 2015 Jul 137 (1): 96-103. Gansmo Liv B, Knappskog Stian, Romundstad Pål, Hveem Kristian, Vatten Lars, Lønning Per |
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients. British journal of cancer 2015 Mar 112 (6): 1114-20. Zajkowicz A, Butkiewicz D, Drosik A, Giglok M, Suwi?ski R, Rusin |
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016 Feb . Gansmo Liv B, Bjørnslett Merete, Halle Mari Kyllesø, Salvesen Helga B, Dørum Anne, Birkeland Einar, Hveem Kristian, Romundstad Pål, Vatten Lars, Lønning Per Eystein, Knappskog Sti |
Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis. Disease markers 2016 2016 4585484. Wang Ping, Wang Meilin, Li Sanqiang, Ma Lingjun, Xi Shoumin, He Ji |
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. BMC cancer 2017 Feb 17 (1): 97. Gansmo Liv B, Bjørnslett Merete, Halle Mari Kyllesø, Salvesen Helga B, Romundstad Pål, Hveem Kristian, Vatten Lars, Dørum Anne, Lønning Per E, Knappskog Sti |
Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy. Bulletin of experimental biology and medicine 2020 Aug 169 (4): 486-490. Zavarykina T M, Tyulyandina A S, Khokhlova S V, Khabas G N, Asaturova A V, Nosova Yu A, Brenner P K, Kapralova M A, Atkarskaya M V, Khodyrev D S, Burdennyi A M, Loginov V I, Stenina M B, Sukhikh G |
Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2021 Feb 1-7. Helwa Reham, Gansmo Liv B, Bjørnslett Merete, Halle Mari Kyllesø, Werner Henrica M J, Romundstad Pål, Hveem Kristian, Vatten Lars, Dørum Anne, Lønning Per E, Knappskog Sti |
Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients. Bulletin of experimental biology and medicine 2021 Oct . Zavarikina T M, Khokhlova S V, Tyulyandina A S, Khabas G N, Asaturova A V, Nosova Yu V, Brenner P K, Kapralova M A, Khodirev D S, Stenina M |
Identification of MDM2 as a prognostic and immunotherapeutic biomarker in a comprehensive pan-cancer analysis: A promising target for breast cancer, bladder cancer and ovarian cancer immunotherapy. Life sciences 2023 6 121832. Jialiang Zheng, Fenglin Miao, Zhao Wang, Yuan Ma, Zhenhang Lin, Yaqin Chen, Xu Kong, Yue Wang, Aobo Zhuang, Ting Wu, Wengang |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source: